Pyrazoloacridine (BioDeep_00000182740)

   

human metabolite blood metabolite


代谢物信息卡片


(3-{4-methoxy-10-nitro-8,14,15-triazatetracyclo[7.6.1.0^{2,7}.0^{13,16}]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-14-yl}propyl)dimethylamine

化学式: C19H21N5O3 (367.16443160000006)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CN(C)CCCN1C2=C3C(=C(C=C2)[N+](=O)[O-])NC4=C(C3=N1)C=C(C=C4)OC
InChI: InChI=1S/C19H21N5O3/c1-22(2)9-4-10-23-15-7-8-16(24(25)26)19-17(15)18(21-23)13-11-12(27-3)5-6-14(13)20-19/h5-8,11,20H,4,9-10H2,1-3H3

描述信息

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D007364 - Intercalating Agents
D000970 - Antineoplastic Agents

同义名列表

5 个代谢物同义名

(3-{4-methoxy-10-nitro-8,14,15-triazatetracyclo[7.6.1.0^{2,7}.0^{13,16}]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-14-yl}propyl)dimethylamine; 9-Methoxy-N,N-dimethyl-5-nitropyrazolo(3,4,5-K)acridine-2(6H)-propanamine; NSC 366140, Methanesulfonate salt; Pyrazoloacridine mesylate; Pyrazoloacridine



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Joel M Reid, Denise L Walker, Jennifer K Miller, Linda M Benson, Andrew J Tomlinson, Stephen Naylor, April L Blajeski, Patricia M LoRusso, Matthew M Ames. The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Feb; 10(4):1471-80. doi: 10.1158/1078-0432.ccr-0557-03. [PMID: 14977851]
  • Jean L Grem, Nancy Harold, Bruce Keith, Alice P Chen, Viven Kao, Chris H Takimoto, J Michael Hamilton, Janet Pang, Marie Pace, Gada B Jasser, Mary G Quinn, Brian P Monahan. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Jul; 8(7):2149-56. doi: NULL. [PMID: 12114415]
  • J P Kuebler, G W King, P Triozzi, T Moore, E H Kraut. Phase II study of pyrazoloacridine in metastatic renal cell carcinoma. Investigational new drugs. 2001; 19(4):327-8. doi: 10.1023/a:1010622129173. [PMID: 11561693]
  • R Pelley, R Ganapathi, L Wood, L Rybicki, D McLain, G T Budd, D Peereboom, T Olencki, R M Bukowski. A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer. Cancer chemotherapy and pharmacology. 2000; 46(3):251-4. doi: 10.1007/s002800000139. [PMID: 11021744]
  • S L Berg, S M Blaney, P C Adamson, M O'Brien, D G Poplack, C Arndt, J Blatt, F M Balis. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Jan; 16(1):181-6. doi: 10.1200/jco.1998.16.1.181. [PMID: 9440741]
  • E J Small, L J Fippin, S P Whisenant. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer. Cancer investigation. 1998; 16(7):456-61. doi: 10.3109/07357909809011699. [PMID: 9774952]
  • W J Berg, J McCaffrey, L H Schwartz, T Mariani, M Mazumdar, R J Motzer. A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma. Investigational new drugs. 1998 199; 16(4):337-40. doi: 10.1023/a:1006143008040. [PMID: 10426668]
  • A L Jayewardene, J E Santoro, J G Gambertoglio. High-performance liquid chromatographic determination of pyrazoloacridine, a nitro-9-methoxyacridine anticancer agent, in human plasma. Journal of chromatography. B, Biomedical sciences and applications. 1997 Nov; 702(1-2):203-10. doi: 10.1016/s0378-4347(97)00363-0. [PMID: 9449572]
  • E Palomino, B Foster, M Kempff, T Corbett, R Wiegand, J Horwitz, L Baker. Identification and antitumor activity of a reduction product in the murine metabolism of pyrazoloacridine (NSC-366140). Cancer chemotherapy and pharmacology. 1996; 38(5):453-8. doi: 10.1007/s002800050510. [PMID: 8765439]
  • P LoRusso, B J Foster, E Poplin, J McCormick, M Kraut, L Flaherty, L K Heilbrun, M Valdivieso, L Baker. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). Clinical cancer research : an official journal of the American Association for Cancer Research. 1995 Dec; 1(12):1487-93. doi: NULL. [PMID: 9815948]
  • B J Foster, R A Wiegand, P M LoRusso, L H Baker. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1. Clinical cancer research : an official journal of the American Association for Cancer Research. 1995 Aug; 1(8):831-7. doi: NULL. [PMID: 9816052]
  • S L Berg, F M Balis, C L McCully, K S Godwin, D G Poplack. Pharmacokinetics of pyrazoloacridine in the rhesus monkey. Cancer research. 1991 Oct; 51(20):5467-70. doi: NULL. [PMID: 1913666]
  • P LoRusso, A J Wozniak, L Polin, D Capps, W R Leopold, L M Werbel, L Biernat, M E Dan, T H Corbett. Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer research. 1990 Aug; 50(16):4900-5. doi: NULL. [PMID: 2165850]